Dec. 25 at 6:14 PM
$JANX
Janux Therapeutics' (JANX) experimental cancer drug JANX008 is moving forward after the company reported new dosing and safety progress and began testing in specific tumor groups, Wedbush said Wednesday in a report.
The update suggests key dosing and safety questions have been resolved with a "more significant readout" expected in 2026, despite limited Phase 1a data disclosure, Wedbush said.
Upcoming pipeline catalysts include a 1H 2026 trial start for the CD19 ARM platform, ongoing preclinical work on the Trop2 TRACTr, and a 2H 2026 combination study of JANX007 with a PSMA x CD28 bispecific, the report said.
Wedbush cited encouraging previous JANX007 data and said CD28-mediated T-cell activation may further improve response durability.
Janux remains well positioned for continued development, supported by a cash balance of
$989 million as of Q3 2025, the report said.
Wedbush maintained its outperform rating on Janux stock with a price target of
$45.
